Why the study?
Does lacking functional TRPV1 improve heart function and reduce hypertrophic markers in mice with pressure overload cardiac hypertrophy?
Does lacking functional TRPV1 improve heart function and reduce hypertrophic markers in mice with pressure overload cardiac hypertrophy?
Answers are grounded in this paper and cite their sources.
TRPV1 plays a role in the progression of cardiac hypertrophy and represents a potential therapeutic target for the treatment of cardiac hypertrophy and heart failure.
TRPV1 (transient receptor potential cation channel, subfamily V, member 1) is best studied in peripheral sensory neurons as a pain receptor; however TRPV1 is expressed in numerous tissues and cell types including those of the cardiovascular system. TRPV1 expression is upregulated in the hypertrophic heart, and the channel is positioned to receive stimulatory signals in the hypertrophic heart. We hypothesized that TRPV1 has a role in regulating cardiac hypertrophy. Using transverse aortic constriction to model pressure overload cardiac hypertrophy we show that mice lacking functional TRPV1, compared to wild type, have improved heart function, and reduced hypertrophic, fibrotic and apoptotic markers. This suggests that TRPV1 plays a role in the progression of cardiac hypertrophy, and presents a possible therapeutic target for the treatment of cardiac hypertrophy and heart failure.
No takes yet. Share an insight, caveat, or question.
Buckley et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: